Patent App 1 relates to creating better imaging and treatment of subtypes found within GI tract, Adrenal and Pancreatic cancers. Relacorilant is used with somatostatin analogs (e.g. Signifor, octreotide) to help image tumors with poor somatostatin expression. This expression provides better imaging.
Patent 2 refers to relacorilant’s (and other GR drugs’) ability to restore regular clotting. This is accomplished by normalizing Factor VIII & VWF, and thrombin-antithrombin levels.
With excess clotting, Cushing’s patients have higher risks for stroke, thrombosis, and fatality. Medical therapy with Korlym competitors including Signifor, ketoconazole, and cabergoline appear ineffective. On the other hand, relacorilant appears to normalize Factor VIII levels.
Patent App 3 extends relacorilant’s IP to certain softgel capsule formulations
Patent App 4 is about a personalized medicine method in which cancer patients are:
a) Assessed baseline expression of certain genes (found amenable to GR drug treatment);
b) Then given a GR drug (e.g. relacorilant or exicorilant) + chemotherapy (e.g. Abraxane);
c) and then assessed for changes from the gene expression baselines.
Corcept is seeking to protect the typical approach to personalized cancer treatment with GR drugs involving designated genes.